Omalizumab is indicated for which of the following conditions –
**Core Concept**
Omalizumab is a recombinant humanized monoclonal antibody that targets the high-affinity IgE receptor (FcεRI) on mast cells and basophils. By binding to IgE, it prevents its interaction with the receptor, thereby inhibiting the release of histamine and other mediators in allergic reactions.
**Why the Correct Answer is Right**
Omalizumab is specifically indicated for the treatment of moderate to severe persistent allergic asthma that is inadequately controlled with inhaled corticosteroids. It also has a role in the management of chronic spontaneous urticaria (CSU) that is resistant to other treatments. By reducing IgE levels, omalizumab decreases the severity of allergic symptoms and improves quality of life.
**Why Each Wrong Option is Incorrect**
* **Option A:** Omalizumab is not used for the treatment of chronic obstructive pulmonary disease (COPD). While both asthma and COPD are respiratory conditions, they have different underlying pathophysiologies, and omalizumab's mechanism of action is specific to allergic asthma.
* **Option B:** Omalizumab is not indicated for the treatment of acute allergic reactions, such as anaphylaxis. While it may be used in the long-term management of allergies, it is not a rescue medication for acute reactions.
* **Option C:** Omalizumab is not used for the treatment of atopic dermatitis (eczema). While both conditions are related to allergies, the pathophysiology and treatment of atopic dermatitis differ from those of allergic asthma.
**Clinical Pearl / High-Yield Fact**
Omalizumab is administered subcutaneously every 2-4 weeks, and its dosage is based on the patient's IgE levels and body weight. It is essential to monitor IgE levels and adjust the dose accordingly to maintain optimal efficacy and minimize the risk of adverse effects.
**Correct Answer: C. Chronic spontaneous urticaria (CSU) that is resistant to other treatments.**